NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.
Yusheng Qu., Robert Kirby., Richard Davies., Ayesha Jinat., Stefano Stabilini., Bin Wu., Longchuan Yu., BaoXi Gao., and Hugo M. Vargas. (2023). Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays. Nucleic Acid Therapeutics. Nucleic Acid Therapeutics, 2022.
This publication was awarded the '2024 Technology Innovation Publication Award' by the Safety Pharmacology Society.
NS5806, widely used as a Kv4-selective activator, also activates TREK-1 and TREK-2 potassium channels.
Nature Communications paper ‘The nucleobase guanine at the 3′-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity'